Emerging new approaches for the treatment of acute promyelocytic leukemia

Jae Park, Joseph G. Jurcic, Todd Rosenblat, Martin S. Tallman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

The introduction of all-trans retinoic acid (ATRA) in the late 1980s combined with anthracycline-based chemotherapy has revolutionized the prognosis of acute promyelocytic leukemia (APL) with more than 90% complete response rates and cure rates of approximately 80%. The subsequent advent of arsenic trioxide (ATO) in 1990s and progress in the treatment of APL have changed its course from a highly fatal to a highly curable disease. Despite the dramatic improvement in clinical outcome of APL, treatment failure still occurs due most often to early death. Relapse has become increasingly less frequent, most commonly occurring in patients with high-risk disease. A major focus of research for the past decade has been to develop risk-adapted and rationally targeted nonchemotherapy treatment strategies to reduce treatment-related morbidity and mortality to low- and intermediate-risk or older patients while targeting more intensive or alternative therapy to those patients at most risk of relapse. In this review, emerging new approaches to APL treatment with special emphasis on strategies to reduce early deaths, risk-adapted therapy during induction, consolidation and maintenance, as well as an overview of current and future clinical trials in APL will be discussed.

Original languageEnglish (US)
Pages (from-to)335-352
Number of pages18
JournalTherapeutic Advances in Hematology
Volume2
Issue number5
DOIs
StatePublished - Oct 2011

Keywords

  • acute promyelocytic leukemia

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Emerging new approaches for the treatment of acute promyelocytic leukemia'. Together they form a unique fingerprint.

Cite this